Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Everest Starts China Phase III Trial of ADC for Urothelial Cancer

publication date: Aug 26, 2021

Shanghai Everest Medicines has begun a China Phase III trial of sacituzumab govitecan-hziy in patients with metastatic urothelial cancer. The Everest trial is the China arm of a global test of the drug being conducted by Gilead. The candidate is a first-in-class, antibody-drug conjugate aimed at TROP-2, which is over-expressed in many epithelial cancers. In 2019, Everest entered an $835 million agreement ($65 million upfront) to acquire China rights to the ADC. Everest completed a $451 million IPO in Hong Kong last year. More details....

Stock Symbols: (HK: 1952) (NSDQ: GILD)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital